VXLL.F Stock Overview
A biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vaxil Bio Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.008 |
| 52 Week High | CA$0.06 |
| 52 Week Low | CA$0.0021 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 33.33% |
| 1 Year Change | -60.00% |
| 33 Year Change | -86.89% |
| 5 Year Change | -75.02% |
| Change since IPO | -95.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| VXLL.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.3% |
| 1Y | -60.0% | 23.6% | 35.1% |
Return vs Industry: VXLL.F underperformed the US Biotechs industry which returned 15.7% over the past year.
Return vs Market: VXLL.F underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| VXLL.F volatility | |
|---|---|
| VXLL.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VXLL.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VXLL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | David Goren | vaxil-bio.com |
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate.
Vaxil Bio Ltd. Fundamentals Summary
| VXLL.F fundamental statistics | |
|---|---|
| Market cap | US$1.00m |
| Earnings (TTM) | -US$137.13k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.3x
P/E RatioIs VXLL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VXLL.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$187.00k |
| Earnings | -CA$187.00k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0014 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VXLL.F perform over the long term?
See historical performance and comparison